Hayward, sorry mix-up or miss understood the question.
I guess that if there is an after treatment with Bavi, certainly after the trial has been unblinded, PPHM always knows. They produce it and pay for it.
I am not sure, giving the dose switching, that PPHM is eager to communicate much about the PII. Even on the good side it took 3 lined up PPHM Managers before Dr. Brekken could answer a question at NYAS about it to say the PII results where actually better then officially announced now they know how the dose switching occurred.
So personally I don't expect communications in the sense that you suggest.
Market Data 
Markets 
AI
